Complex and defined biostructures with the dock-and-lock method

Trends in Pharmacological Sciences

Volumn 33, Issue 9, 2012, Pages 474-481

  Rossi, Edmund A ^a   Goldenberg, David M ^a,b,c   Chang, Chien Hsing ^a,b  

^a IBC Pharmaceuticals Inc   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 RAP; 22 RAP; ALPHA2B INTERFERON; ANTIBODY CONJUGATE; C2 RAP; CD20 ANTIBODY; CD74 ANTIBODY; E1 RAP; ENFUVIRTIDE; EPRATUZUMAB; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEXAVALENT ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MILATUZUMAB; MONOCLONAL ANTIBODY; RAP PROTEIN; TF2; UNCLASSIFIED DRUG; VELTUZUMAB;

ANTIBODY SPECIFICITY; BINDING SITE; CHEMICAL MODIFICATION; COLORECTAL CANCER; CONJUGATION; DOCK AND LOCK METHOD; DRUG ACTIVITY; DRUG BINDING; DRUG DEVELOPMENT; DRUG SPECIFICITY; DRUG STRUCTURE; LUNG CANCER; PEGYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SUBUNIT; REVIEW;

EID: 84865212772     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.06.001     Document Type: Short Survey

References (56)

1. H.K. Binz Engineering novel binding proteins from nonimmunoglobulin domains Nat. Biotechnol. 23 2005 1257 1268 (Pubitemid 41486853)
2. H.K. Binz, and A. Pluckthun Engineered proteins as specific binding reagents Curr. Opin. Biotechnol. 16 2005 459 469 (Pubitemid 41114852)
3. A.M. Cuesta Multivalent antibodies: when design surpasses evolution Trends Biotechnol. 28 2010 355 362
4. T. Hey Artificial, non-antibody binding proteins for pharmaceutical and industrial applications Trends Biotechnol. 23 2005 514 522 (Pubitemid 41317915)
5. R.J. Hosse A new generation of protein display scaffolds for molecular recognition Protein Sci. 15 2006 14 27 (Pubitemid 43004229)
6. U. Kishore A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway J. Immunol. 166 2001 559 565 (Pubitemid 32038477)
7. S.A. Kostelny Formation of a bispecific antibody by the use of leucine zippers J. Immunol. 148 1992 1547 1553
8. P. Pack Tetravalent miniantibodies with high avidity assembling in Escherichia coli J. Mol. Biol. 246 1995 28 34
9. A.V. Terskikh 'Peptabody': a new type of high avidity binding protein Proc. Natl. Acad. Sci. U.S.A. 94 1997 1663 1668
10. J. Willuda Tumor targeting of mono-, di-, and tetravalent anti-p185 (HER-2) miniantibodies multimerized by self-associating peptides J. Biol. Chem. 276 2001 14385 14392
11. E.A. Rossi The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures Bioconjug. Chem 23 2012 309 323
12. E.A. Rossi Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting Proc. Natl. Acad. Sci. U.S.A. 103 2006 6841 6846
13. G.S. Baillie Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract FEBS Lett. 579 2005 3264 3270 (Pubitemid 40804673)
14. W. Wong, and J.D. Scott AKAP signaling complexes: focal points in space and time Nat. Rev. Mol. Cell Biol. 5 2004 959 970 (Pubitemid 39611533)
15. D.W. Carr Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif J. Biol. Chem. 266 1991 14188 14192 (Pubitemid 21907482)
16. M. Colledge, and J.D. Scott AKAPs: from structure to function Trends Cell Biol. 9 1999 216 221 (Pubitemid 29244132)
17. M.G. Newlon The molecular basis for protein kinase A anchoring revealed by solution NMR Nat. Struct. Biol. 6 1999 222 227 (Pubitemid 29107224)
18. M.G. Newlon A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes EMBO J. 20 2001 1651 1662 (Pubitemid 32299402)
19. N.M. Alto Bioinformatic design of A-kinase anchoring protein in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring Proc. Natl. Acad. Sci. U.S.A. 100 2003 4445 4450 (Pubitemid 36457750)
20. M.V. Backer Self-assembled 'dock and lock' system for linking payloads to targeting proteins Bioconjug. Chem. 17 2006 912 919 (Pubitemid 44162608)
21. I. Burbulis Using protein-DNA chimeras to detect and count small numbers of molecules Nat. Methods 2 2005 31 37 (Pubitemid 41131055)
22. S.M. Deyev Design of multivalent complexes using the barnase· barstar module Nat. Biotechnol. 21 2003 1486 1492 (Pubitemid 37522710)
23. C.D. Hodneland Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands Proc. Natl. Acad. Sci. U.S.A. 99 2002 5048 5052 (Pubitemid 34411501)
24. R.B. Pepinsky Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity J. Pharmacol. Exp. Ther. 297 2001 1059 1066 (Pubitemid 32472504)
25. L.P. Tan Improving the intein-mediated, site-specific protein biotinylation strategies both in vitro and in vivo Bioorg. Med. Chem. Lett. 14 2004 6067 6070
26. E.A. Rossi Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics Cancer Res. 68 2008 8384 8392
27. E.A. Rossi Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood 113 2009 6161 6171
28. E.A. Rossi CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood 114 2009 3864 3871
29. E.A. Rossi A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells Cancer Res. 70 2010 7600 7609
30. C.H. Chang A new method to produce monoPEGylated dimeric cytokines shown with human interferon-alpha2b Bioconjug. Chem. 20 2009 1899 1907
31. R.D. Blumenthal Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen) Cancer Res. 65 2005 8809 8817 (Pubitemid 41377369)
32. E.A. Rossi Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy Clin. Cancer Res. 9 2003 3886S 3896S (Pubitemid 37169195)
33. R.M. Sharkey Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy Semin. Nucl. Med. 40 2010 190 203
34. E.A. Rossi Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers Blood 118 2011 1877 1884
35. Chang, C-H. and Goldenberg, D.M. IBC Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA, US2011/012346A1
36. Chang, C-H. et al. IBC Pharmaceuticals, Inc. and Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity, US2011/0274704A1
37. A. Makinson, and J. Reynes The fusion inhibitor enfuvirtide in recent antiretroviral strategies Curr. Opin. HIV AIDS 4 2009 150 158
38. Chang, C-H. et al. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. PLoS ONE (in press)
39. 18F radiolabeling for PET J. Nucl. Med. 50 2009 991 998
40. 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice J. Nucl. Med. 51 2010 1780 1787
41. R.M. Sharkey Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model Radiology 246 2008 497 507
42. D.V. Gold A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma Cancer Res. 68 2008 4819 4826
43. D.M. Goldenberg Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting J. Nucl. Med. 49 2008 158 163
44. 90Y-IMP-288 alone and combined with gemcitabine J. Nucl. Med. 50 2009 2008 2016
45. 68Ga J. Nucl. Med. 52 2011 555 559
46. 18F-labeled hapten peptide in mice with human tumor xenografts Mol. Cancer Ther. 9 2010 1019 1027
47. R.M. Sharkey Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update Clin. Cancer Res. 13 2007 5577s 5585s (Pubitemid 47510390)
48. R.M. Sharkey Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody Cancer Res. 68 2008 5282 5290
49. R.M. Sharkey Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma J. Nucl. Med. 50 2009 444 453
50. R.M. Sharkey Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies Cancer Biother. Radiopharm. 25 2010 1 12
51. R. Stein Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma Clin. Cancer Res. 10 2004 2868 2878 (Pubitemid 38509167)
52. J. Carnahan Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab Mol. Immunol. 44 2007 1331 1341 (Pubitemid 44415959)
53. P. Gupta Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias Blood 116 2010 3258 3267
54. P. Gupta Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas Blood 119 2012 3767 3778
55. C. Xuan Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma Blood 115 2010 2864 2871
56. R. Stein Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways Blood 115 2010 5180 5190